FindTrial
Sign In

Characterization of germline mutations in patients with gastric cancer or gastric precancerous lesions

Study on clinical application of germline mutation testing in precision screening for gastric cancer using microfluidic technology and next generation sequencing (NGS)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053617
Enrollment
Unknown
Registered
2021-11-25
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer and gastric precancerous lesions

Interventions

gastric cancer or high-grade neoplasia group:None
benign or no gastric lesions group:None

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Han population, aged 18 to 70 years, no gender preference; 2.Patients who were pathologically diagnosed with precancerous lesions such as gastric cancer or high-grade neoplasia by endoscopic examination and gastric mucosal biopsy (case group) and patients with benign or no gastric lesions (control group); 3.There is no restriction on family history of cancer.

Exclusion criteria

Exclusion criteria: 1.Patients who have been diagnosed with tumors of organs other than the stomach; 2.Special groups (such as women with mental illness, cognitive dysfunction, pregnancy and lactation, etc.).

Design outcomes

Primary

MeasureTime frame
Whether they carry germline mutation of genes associated with gastric cancer;—

Countries

China

Contacts

Public ContactLi Baiwen

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

muzibowen@126.com+86 18930894343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026